TP53 and cancer: Eprenetapopt (APR-246), developed by Aprea Therapeutics, is a small-molecule Michael acceptor designed to reactivate mutant or inactivated p53 proteins by restoring their normal conformation and function, thereby inducing programmed cell death in cancer cells.